Ozempic

Caloric Restriction, at least one weight-related comorbid condition, Obesity + 6 more
Treatment
6 FDA approvals
20 Active Studies for Ozempic

What is Ozempic

SemaglutideThe Generic name of this drug
Treatment SummarySemaglutide is a medication used to treat type 2 diabetes. It works by stimulating insulin production and reducing blood sugar levels. It is available in two forms: injections that are given once a week and tablets that are taken once a day. Clinical trials have shown that semaglutide can lower the levels of glycosylated hemoglobin (HbA1c) and reduce body weight. In 2021, semaglutide was approved by the FDA and Health Canada for use in adults with general obesity or overweight who have at least one weight-related condition. This makes semaglutide the first drug
Ozempicis the brand name
image of different drug pills on a surface
Ozempic Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ozempic
Semaglutide
2017
19

Approved as Treatment by the FDA

Semaglutide, commonly known as Ozempic, is approved by the FDA for 6 uses including Type 2 Diabetes Mellitus and Cardiovascular Events .
Type 2 Diabetes Mellitus
Cardiovascular Events
Type 2 Diabetes
Cardiovascular Diseases
Physical Activity
Used in combination with other therapies
Diet
Used in combination with other therapies

Effectiveness

How Ozempic Affects PatientsSemaglutide helps to reduce levels of HbA1c, blood pressure, and body weight. It does this by increasing insulin production and decreasing the amount of glucagon in the body. It also lowers triglycerides and VLDL cholesterol, which can help improve cardiovascular health. There is a risk of developing medullary thyroid cell cancer, pancreatitis, and dehydration while taking semaglutide. It is important to stay hydrated and seek medical attention right away if experiencing abdominal pain. Additionally, this drug may affect how other drugs taken orally are absorbed, so it's important to monitor for both positive and negative
How Ozempic works in the bodySemaglutide helps to keep blood sugar levels in check by stimulating the pancreas to produce insulin. It also slows down the digestion of food and reduces the amount of glucagon released after meals. Semaglutide binds to the GLP-1 receptor in the body, activating several processes that lower blood sugar. Additionally, semaglutide may reduce the progression of atherosclerosis, a type of heart disease, by decreasing inflammation and gut permeability. Finally, semaglutide can also lead to weight loss through its effects on appetite and food cravings.

When to interrupt dosage

The dosage of Ozempic is contingent upon the diagnosed issue, such as Type 2 Diabetes, at least one weight-related comorbid condition and reduced-calorie diet. The sum of medication also fluctuates in accordance with the technique of delivery (e.g. Solution - Subcutaneous or Subcutaneous) specified in the table beneath.
Condition
Dosage
Administration
Obesity
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Physical Activity
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Type 2 Diabetes
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Diet
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Chronic Weight Management therapy
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Cardiovascular Diseases
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Caloric Restriction
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
at least one weight-related comorbid condition
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Cardiovascular Events
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution - Subcutaneous, Solution, Subcutaneous, , Injection, solution, Injection, solution - Subcutaneous, Tablet, Tablet - Oral, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Warnings

Ozempic Contraindications
Condition
Risk Level
Notes
Multiple Endocrine Neoplasia
Do Not Combine
Thyroid Neoplasms
Do Not Combine
Medullary carcinoma of thyroid
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Semaglutide may interact with Pulse Frequency
There are 20 known major drug interactions with Ozempic.
Common Ozempic Drug Interactions
Drug Name
Risk Level
Description
Acetohexamide
Moderate
Semaglutide may increase the hypoglycemic activities of Acetohexamide.
Carbutamide
Moderate
Semaglutide may increase the hypoglycemic activities of Carbutamide.
Chlorpropamide
Moderate
Semaglutide may increase the hypoglycemic activities of Chlorpropamide.
Englitazone
Moderate
The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Englitazone.
Fluconazole
Moderate
The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Fluconazole.
Ozempic Toxicity & Overdose RiskSome people have overdosed on Semaglutide and experienced nausea as the primary symptom. All those who have overdosed have recovered fully with the help of medical care. It can take up to one week for Semaglutide to leave the body, so observation and treatment may be necessary for a while. There is no specific antidote for an overdose on this drug.
image of a doctor in a lab doing drug, clinical research

Ozempic Novel Uses: Which Conditions Have a Clinical Trial Featuring Ozempic?

196 active studies are currently underway to assess the effectiveness of Ozempic in treating Disease, Weight-Related Comorbidities and BMI >27 kg/m2.
Condition
Clinical Trials
Trial Phases
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Cardiovascular Diseases
0 Actively Recruiting
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Cardiovascular Events
4 Actively Recruiting
Not Applicable
at least one weight-related comorbid condition
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Caloric Restriction
0 Actively Recruiting
Obesity
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1

Ozempic Reviews: What are patients saying about Ozempic?

5Patient Review
10/16/2022
Ozempic for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
I've been on this medication for four months now. I definitely noticed a change in my cravings; I used to love greasy foods, but now they don't appeal to me at all. I'm down 31 pounds since starting the medication, and I don't feel the need to snack constantly like I used to.
5Patient Review
10/29/2022
Ozempic for Weight Loss Management for an Obese Person
I've lost 35lbs since starting this treatment in July. The side effects were unpleasant at first, but they've gone away now and I'm really happy with the results. It's important to drink lots of water when you're on this medication, and to be patient as your body adjusts to it. The constipation was the hardest part for me, but it eventually went away.
5Patient Review
11/4/2022
Ozempic for Type 2 Diabetes Mellitus
This is the best medication I've ever been on. In just four months, it's helped me lower my A1C from 11 to 7. Plus, I haven't experienced any negative side effects.
4.3Patient Review
10/21/2022
Ozempic for Type 2 Diabetes Mellitus
Just feeling sick... otherwise this treatment is working well.
3Patient Review
11/8/2022
Ozempic for Weight Loss Management for an Obese Person
I get very nauseous from this medication, to the point of vomiting. The taste is incredibly unpleasant as well.
2.3Patient Review
11/5/2022
Ozempic for Type 2 Diabetes Mellitus
I took a one shot Monday night and was in the ER 5 days later. Spent over night and went home next night and was diagnosed with Pancreatitis. I have since been Diagnosed with Pancreas Cancer and seeing a Specialist Tuesday to see the depth of my Cancer. Ozempic may have alerted me of something far worst to come or it caused my Pancretitis. I won't be taking it again. Male 59
2Patient Review
11/7/2022
Ozempic for Weight Loss Management for an Obese Person
I would not recommend this drug for weight loss. It gave me terrible constipation that I have never experienced before in my life. I was on it for 5 weeks and stopped immediately after feeling these effects.
1.7Patient Review
10/30/2022
Ozempic for Type 2 Diabetes Mellitus
I have been experiencing gut pain, nausea, and headaches since I started taking this medication six weeks ago. I am also constantly constipated and have gained twelve pounds. While my A1C has dropped from 12.1 to 6.1 in the same time frame, I can't say that this drug is worth the other side effects I've experienced.
1.3Patient Review
10/16/2022
Ozempic for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
Allergic dermatitis is a terrible reaction to have. I had red splotches, dry patches, and hive-like itching all over my face. If anyone has experienced this, please let me know what the remedy was.
1Patient Review
10/7/2022
Ozempic for Type 2 Diabetes Mellitus
I was really surprised that this drug is allowed on the market after experiencing its terrible side effects firsthand. I had stomach aches, diarrhea and vomiting when I took the full dose. No wonder people lose weight when they're too sick to eat!
1Patient Review
10/18/2022
Ozempic for Type 2 Diabetes Mellitus
I have been struggling with chronic gastritis for a while now. I was put on Ozempic .25 five weeks ago, and my doctor has finally listened to me about the severe stomach pain I've been experiencing. This medication is being taken off of my regimen because it's made me feel incredibly ill--I have never felt this way from a medication before. It did help lower my blood sugar into the normal range, but the stomach pain is so unbearable that I would rather not have any relief than go through this again. If only I had found these reviews before starting this med...
1Patient Review
11/2/2022
Ozempic for Type 2 Diabetes Mellitus
After my first injection of this medication, I was beset by vomiting and diarrhea for six days straight. This led to extreme dehydration and a potassium deficiency that could've resulted in a heart attack. Needless to say, I won't be taking this drug any longer.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ozempic

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What exactly does Ozempic do?

"Ozempic, when used with diet and exercise, has been shown to improve blood sugar in adults with type 2 diabetes. In adults with type 2 diabetes and known heart disease, Ozempic reduces the risk of major cardiovascular events such as stroke, heart attack, or death."

Answered by AI

Is Ozempic for weight loss?

"Ozempic is a medication for adults with type 2 diabetes. It is not a weight-loss drug. Ozempic, combined with diet and exercise, may improve blood sugar."

Answered by AI

What are the most common side effects of Ozempic?

"These are some of the side effects that may occur when using semaglutide. If you experience any of these effects, tell your doctor or pharmacist."

Answered by AI

What are the dangers of Ozempic?

"The pancreas can become inflamed, which is called pancreatitis. This can cause changes in vision, low blood sugar (hypoglycemia), kidney problems (kidney failure), serious allergic reactions, and gallbladder problems."

Answered by AI

Clinical Trials for Ozempic

Image of KPNC Division of Research in Pleasanton, United States.

MetSense Risk Flag for Type 2 Diabetes

18+
All Sexes
Pleasanton, CA
People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.
Waitlist Available
Has No Placebo
KPNC Division of ResearchEsti Iturralde, PhD
Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Have you considered Ozempic clinical trials? We made a collection of clinical trials featuring Ozempic, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Ozempic clinical trials? We made a collection of clinical trials featuring Ozempic, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Have you considered Ozempic clinical trials? We made a collection of clinical trials featuring Ozempic, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security